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Abstract
Calciphylaxis is a rare but potentially fatal condition occurring in patients with end stage renal
disease on dialysis. Due to interplay of various factors, disturbances occur in the metabolism of
calcium and phosphate leading to calcification within the vessel walls. The net result is tissue
ischemia and necrosis. Clinically this presents as painful non-healing skin ulcers, which contribute
to significant morbidity and mortality due to septic progression of the lesion. In this case report,
we highlight the rapidly progressive nature of this disease, its etiopathogenesis and the role of early
diagnosis in preventing life-threatening complications.
Introduction
A 44-year-old Caucasian female with chronic renal failure
receiving dialysis for the past one year presented to our
hospital complaining of two weeks of diarrhea and wors-
ening nausea. She was scheduled to receive dialysis treat-
ments thrice weekly but had continuously missed her
scheduled appointments. At the time of her initial presen-
tation she had not been dialyzed for the past two weeks.
Her past medical history was also significant for type 2
diabetes mellitus, hypertension, dyslipidemia, anemia of
chronic disease and bronchial asthma. She had a history
of cholecystectomy and cesarean section. There was a
strong family history of hypertension, coronary artery dis-
ease and diabetes mellitus. She denied smoking, alcohol
intake or use of recreational drugs. Her current medica-
tions included Vicodin, Actos, insulin and albuterol HFA.
She had history of allergy to Penicillin.
Physical examination
On examination she was disabled with morbid obesity
and in no apparent distress. There was no evidence of pal-
lor, cyanosis or jaundice. Her vital signs revealed heart rate
of 106/min, BP 140/78 mm of Hg, temperature 95.4°F,
respiratory rate 18/min, and saturating at 99% on room
air. She had a surgically implanted left subclavian dialysis
catheter. HEENT exam revealed mild dehydration. Sys-
temic examination was significant for mild epigastric ten-
derness without guarding or rigidity. There were areas of
ecchymoses over inner thighs. Peripheral pulses were nor-
mal.
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Laboratory tests
Laboratory investigations revealed potassium of 3.1 mg/
dL, bicarbonate 22 mEq/L, BUN 74 mg/dl, creatinine 6.3
mg/dl, anion gap 20 mEq/L, phosphorous 7.2 mg/dL,
serum calcium 9.1 mg/dL, magnesium 1.5 mg/dL, hemo-
globin 10.5 g/dL, hematocrit 30%, serum iron 29 mcg/dL,
TIBC 84 mcg/dL, normal amylase, lipase, thyroid function
tests and liver function tests except albumin of 1.4 g/dL.
EKG revealed sinus rhythm with RBBB. Chest radiograph
was normal.
Hospital course
The patient was admitted for hemodialysis, correction of
electrolyte imbalance and for evaluation of diarrhea.
Patient was started on epoetin alfa for anemia, sevelamer
hydrochloride (Renagel) for hyperphosphatemia and
heparin for thromboprophylaxis. Over the next several
days, the diarrhea resolved but patient developed worsen-
ing body aches and thigh pain. Blood test revealed leuko-
cytosis at 19.7 × 103/mm3 with neutrophilia at 13.7 × 103/
microL, hemoglobin of 7.9 g/dL, hematocrit 25.3%, with-
out any evidence of bleeding. Stool tests were non-con-
tributory. Blood cultures revealed methicillin sensitive
staphylococcus aureus (MSSA) from the peripheral intra-
venous line as well as a surgically implanted long-term
dialysis catheter (Ash-cath). The site of Ash-cath was ery-
thematous; therefore, it was removed. The patient was
started on ceftriaxone. Over the next couple of days the
patient's ecchymoses over the thighs began to worsen
accompanied with induration, bullae and necrosis. The
lesions started spreading to the lower abdomen as well
(Figures 1 and 2).
Given the typical skin lesions in a patient with DM and
end-stage renal disease (ESRD) on hemodialysis, with an
increased calcium phosphate product (Ca × PO4) at 65.5
mg2/dL2, a diagnosis of Calcific Uremic Arteriopathy
(CUA) was made. Her other risk factors included morbid
obesity, history of treatment with calcium based phos-
phate binder Phoslo, hypoalbuminemia and hyperphos-
phatemia. Further coagulation studies and ANA were
normal, therefore, ruling out a possibility of hypercoagu-
lable conditions or vasculitis. Plastic surgery service per-
formed multiple debridements of the lesions over the
thighs. Biopsy of the lesions revealed chronic skin gan-
grene. Tissue cultures grew vancomycin resistant entero-
coccus (VRE) and MSSA. Appropriate antibiotic therapy
was started based on these sensitivities and daily dialysis
treatments continued. But despite these measures, her
skin lesions continued to worsen. She eventually devel-
oped severe sepsis and septic shock with disseminated
intravascular coagulation (DIC) and passed away.
Discussion
Calciphylaxis, also called Calcific Uremic Arteriopathy
(CUA), is a rare but life-threatening condition character-
ized by vascular calcification and cutaneous necrosis usu-
ally seen in patients with ESRD on long-term dialysis. In
this population, the prevalence of CUA is 4.1% [1]. It was
first described in 1962 by Selye in nephrectomized rats
[2]. Since 1976 this condition has been reported primarily
in patients with ESRD [3]. Although its pathogenesis is
unclear, hypercalcemia, hyperphosphatemia, with an ele-
vated calcium phosphate product, and secondary hyper-
parathyroidism have been implicated in its pathogenesis.
The Ca × PO4 product is derived by multiplying total cal-
cium by phosphate and should normally be less than 30
mg2/dL2 (22.2 – 45.5 mg2/dL2).
There are many risk factors associated with this condition
as highlighted in Table 1[4-11]. Of these factors, some –
A large inner thigh ulcerated lesion with peripheral necrotic  edges surrounded by areas of violaceous skin discoloration. Figure 1
A large inner thigh ulcerated lesion with peripheral 
necrotic edges surrounded by areas of violaceous 
skin discoloration.
Extensive involvement of the thighs and lower abdomen. Figure 2
Extensive involvement of the thighs and lower abdo-
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such as Vitamin D and PTH – are called sensitizers and
others – such as trauma and iron dextran injections – are
called challengers. It is the interaction of sensitizers and
challengers that lead to abnormal calcium and phosphate
metabolism with calcification of small and medium sized
arteries and arterioles leading to occlusion of the vessel
and tissue infarction.
Clinical features
Patients with calciphylaxis present with acute onset of
exquisitely tender cutaneous nodules or plaques with vio-
laceous or black discoloration. The distribution of these
areas can be proximal or distal. In case of proximal distri-
bution, the cutaneous findings appear in areas with high
content of adipose tissue such as trunk, thighs and but-
tocks. This variant carries poor prognosis, while the dis-
tally localized disease, affecting the extremities and digits,
is less severe. Rarely has the disease been found to affect
the face, shoulder, genitalia and internal organs. The
lesions rapidly progress and translate into necrotic non-
healing ulcers and wet gangrene, which tend to get super
infected. Mortality rates double when lesions ulcerate,
reaching as high as 80% [4]. The leading cause of death at
this point becomes sepsis and skin necrosis [8-12].
Diagnosis
Many medical conditions can masquerade CUA, espe-
cially when the disease is distally localized involving the
extremities. Differential diagnoses of CUA are highlighted
in Table 2. Diagnosis is usually based on a triad of find-
ings: characteristic cutaneous features in a uremic patient
with abnormal biochemistry.
Laboratory workup frequently shows hypercalcemia,
hyperphosphatemia, and increased parathyroid hormone
levels. To complete the workup, it is recommended to
obtain coagulation studies, including prothrombin time
(PT), partial thromboplastin time (PTT) and protein C
and S levels to rule out hypercoagulable state. Autoim-
mune workup may be needed also to rule out vasculites.
Imaging studies are not always helpful in diagnosis of
CUA. Plain radiographs and computed tomography may
show linear calcification of vessels. This finding is nonspe-
cific and is commonly encountered in diabetes and ESRD.
Xeroradiography, a high-definition x-ray photography
that tends to improve structure visibility, is the best imag-
ing to study soft tissue calcification [13]. Bone scan is pos-
itive in majority of patients with CUA and can be used to
assess response to treatment. Trans-cutaneous oxygen sat-
uration is low and may aid in the diagnosis of CUA [14].
Biopsy of skin lesion shows calcium deposition in tunica
media of small and medium sized arteries and arterioles
with intimal proliferation, lobular fat necrosis with infil-
tration of neutrophils, lymphocytes and macrophages.
However biopsy is needed only in equivocal cases because
of the risk of biopsy itself leading to development of non-
healing ulcers.
Treatment
Early diagnosis of CUA is necessary to reduce morbidity
and mortality. Management is chiefly supportive and
multidisciplinary. Triggering agents such as warfarin, cor-
ticosteroids, calcium, vitamin D, parenteral iron therapy
should be discontinued. If levels of calcium and phos-
phate and, subsequently Ca × PO4 product are elevated,
they should be normalized with dietary restriction of
phosphorus through low protein diet and usage of cal-
cium free phosphate binders such as sevelamer hydro-
chloride [15-17]. Increasing the frequency of dialysis,
using a low calcium dialysate, is also recommended. Cal-
cimimetics such as cinacalcet can help reduce parathyroid
hormone levels, and hence calcium and phosphorus, in
Table 1: Risk factors for Calciphylaxis.
Patient-related factors Female sex; Caucasian race; Morbid obesity (BMI > 30 kg/m2);
Protein malnutrition (serum albumin ~2 gm/dL);
Recent weight loss (>10% in 6 months).
Biochemical factors Hypercalcemia >10.5 mg/dL; Hyperphosphatemia (>6.5 mg/dL);
Calcium × Phosphate product (Ca × PO4) > 55 mg2/dL2;
Alkaline Phosphatase 10 IU above normal;
Hyperparathyroidism (primary or secondary)
Disease factors ESRD on replacement therapy; Diabetes Mellitus;
Cirrhosis of liver;
Hypercoagulable states (e.g Protein C and S deficiency);
Malignancy, Multiple myeloma, Lymphoma, Cholangiocarcinoma.
Medication-related factors Warfarin therapy; Use of steroids;
Use of vitamin D & calcium based phosphate binders;
Drug infusions such as parenteral iron therapy;
Trauma (e.g. subcutaneous insulin injections).International Archives of Medicine 2009, 2:22 http://www.intarchmed.com/content/2/1/22
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secondary hyperparathyroidism by increasing the sensitiv-
ity of calcium sensing receptors in parathyroid gland [18].
Bisphosphonates, sodium thiosulphate and hyperbaric
oxygen reduce pain and hasten healing [19-21]. Parathy-
roidectomy is indicated in secondary hyperparathy-
roidism with CUA [22]. Pain relief with large doses of
analgesics and lumbar sympathetic blockade may be nec-
essary. Serial debridement of infected necrotic tissue and
broad-spectrum antibiotics aid in wound healing and
treating sepsis.
Conclusion
Calciphylaxis is a rare but fatal disease. Hence great
emphasis needs to be placed on prevention. Patients need
to be educated regarding the importance of compliance
with medications, dialysis, and proper diet and weight
reduction. Avoiding the triggering factors and maintain-
ing normal levels of calcium, phosphate and Ca × PO4
product seems to be the key, although CUA can occasion-
ally occur in the absence of renal disease and a normal Ca
× PO4 product [23-26].
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